The Study of Public Health Policies for Alzheimer’s Disease Based on the Pathogenesis
DOI:
https://doi.org/10.61173/af84mn17Keywords:
Alzheimer’s disease, pathogenesis, public health policyAbstract
In the current social context, the increasing aging population has led to a rising incidence of Alzheimer’s disease (AD). Today’s research primarily focuses on the development of new drugs for AD, exploration of its causes, and the formulation of reasonable policies for AD patients. As of now, there is still no curative drug available for AD. This article mainly analyzes the pathogenesis of AD, discussing its causes, symptoms, diagnostic methods, corresponding public strategies, measures, and care aspects, providing insights for the development of public health policies related to AD. Through this article, people can gain a better understanding of the mechanisms and pathology of AD, as well as the methods and policies for addressing it, while also recognizing the importance of improving public health policies for AD. It offers a general research direction for future studies, particularly concerning unresolved issues related to AD medications. It is hoped that future research will make further progress in developing new drugs specifically for AD.References
[1] Jucker M, Walker LC. Alzheimer’s disease: From immunotherapy to immunoprevention. Cell, 2023, 186(20): 4260-4270.
[2] Liu Y, Shen Y. Applications of Nanoparticles in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 2023, 96(2): 459-471.
[3] Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Current Neuropharmacology, 2020, 18(11): 1106-1125.
[4] Singh AK, Verma S. Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer’s disease. Indian Journal of Ophthalmology, 2020, 68(4): 555-561.
[5] Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs & Aging, 2004, 21(7): 453-478.
[6] Chu LW. Alzheimer’s disease: early diagnosis and treatment. Hong Kong Medical Journal, 2012, 18(3): 228-237.
[7] Molinuevo JL. Memantina [Memantine]. Neurologia, 2003, 18(5): 255-261. (In Spanish).
[8] Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. Journal of Prevention of Alzheimer’s Disease, 2023, 10(3): 362-377.
[9] Wei Ruiyuan. Social Work Intervention Research on Alzheimer’s Disease Patients and Their Caregivers[D]. Inner Mongolia Normal University, 2020.
[10] Atri A. The Alzheimer’s Disease Clinical Spectrum: Diagnosis and Management. Medical Clinics of North America, 2019, 103(2): 263-293.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
